Hurwitz, H., Cushman, S., Jiang, C., Shterev, I., Mahoney, M. R., Niedzwiecki, D., … Nixon, A. B. (2013). Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 31). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Hurwitz, Herbert, Stephanie Cushman, Chen Jiang, Ivo Shterev, Michelle R. Mahoney, Donna Niedzwiecki, Robert J. Mayer, Alan Paul Venook, Kouros Owzar, and Andrew B. Nixon. “Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.

Hurwitz H, Cushman S, Jiang C, Shterev I, Mahoney MR, Niedzwiecki D, et al. Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.

Hurwitz, Herbert, et al. “Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance).” JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 15, AMER SOC CLINICAL ONCOLOGY, 2013.

Hurwitz H, Cushman S, Jiang C, Shterev I, Mahoney MR, Niedzwiecki D, Mayer RJ, Venook AP, Owzar K, Nixon AB. Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.